GlobeNewswire: Leap Therapeutics, Inc. Contains the last 10 of 34 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T10:26:38ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2018/08/08/1548766/0/en/Leap-Therapeutics-Reports-Second-Quarter-2018-Business-Update-and-Financial-Results.html?f=22&fvtc=4&fvtv=31225Leap Therapeutics Reports Second Quarter 2018 Business Update and Financial Results2018-08-08T11:00:00Z<![CDATA[CAMBRIDGE, Mass., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today reported a business update and financial results for the second quarter ended June 30, 2018.]]>https://www.globenewswire.com/news-release/2018/07/23/1540504/0/en/Leap-Therapeutics-Announces-Collaboration-with-Merck-KGaA-Darmstadt-Germany-and-Pfizer-to-Evaluate-Combination-of-TRX518-Avelumab-and-Chemotherapy-in-Advanced-Solid-Tumors.html?f=22&fvtc=4&fvtv=31225Leap Therapeutics Announces Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer to Evaluate Combination of TRX518, Avelumab, and Chemotherapy in Advanced Solid Tumors2018-07-23T11:30:00Z<![CDATA[CAMBRIDGE, Mass., July 23, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced it has entered into a collaboration agreement with Merck KGaA, Darmstadt, Germany, and Pfizer to evaluate Leap’s GITR agonist, TRX518, in combination with avelumab*, a human anti-PD-L1 IgG1 monoclonal antibody, and chemotherapy.]]>https://www.globenewswire.com/news-release/2018/06/13/1520880/0/en/Leap-Therapeutics-to-Present-at-the-2018-JMP-Securities-Life-Sciences-Conference.html?f=22&fvtc=4&fvtv=31225Leap Therapeutics to Present at the 2018 JMP Securities Life Sciences Conference2018-06-13T11:00:00Z<![CDATA[CAMBRIDGE, Mass., June 13, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced that Christopher K. Mirabelli, Ph.D., Chairman, President and Chief Executive Officer, will present a corporate overview at the 2018 JMP Securities Life Sciences Conference, being held in New York City on June 20-21, 2018.]]>https://www.globenewswire.com/news-release/2018/05/11/1500953/0/en/Leap-Therapeutics-Reports-First-Quarter-2018-Financial-Results.html?f=22&fvtc=4&fvtv=31225Leap Therapeutics Reports First Quarter 2018 Financial Results2018-05-11T11:00:00Z<![CDATA[Conference Call with DKN-01 Clinical Investigators Planned for May 18, 2018 Conference Call with DKN-01 Clinical Investigators Planned for May 18, 2018]]>https://www.globenewswire.com/news-release/2018/04/16/1472062/0/en/Leap-Therapeutics-Presents-Nonclinical-and-Clinical-Data-on-DKN-01-at-AACR-2018-Annual-Meeting.html?f=22&fvtc=4&fvtv=31225Leap Therapeutics Presents Nonclinical and Clinical Data on DKN-01 at AACR 2018 Annual Meeting2018-04-16T13:00:00Z<![CDATA[CAMBRIDGE, Mass., April 16, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (NASDAQ:LPTX) today presented nonclinical and clinical data on DKN-01, Leap’s anti-DKK1 monoclonal antibody, at the American Association for Cancer Research (AACR) 2018 Annual Meeting. The presentation highlighted the immunomodulatory activity of DKN-01 in nonclinical experiments and preliminary results from the dose escalation phase of the clinical study evaluating DKN-01 in combination with the Merck (known as MSD outside the United States and Canada) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with advanced esophagogastric cancer.]]>https://www.globenewswire.com/news-release/2018/03/27/1453975/0/en/Leap-Therapeutics-Announces-Closing-of-Public-Offering-of-Common-Stock-and-Full-Exercise-of-Underwriters-Option-to-Purchase-Additional-Shares.html?f=22&fvtc=4&fvtv=31225Leap Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares2018-03-27T20:05:00Z<![CDATA[CAMBRIDGE, Mass., March 27, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the closing of a public offering of 2,146,667 shares of its common stock, which includes the sale of an additional 280,000 shares of its common stock pursuant to the full exercise of the underwriters’ option to purchase additional shares. Total gross proceeds to Leap from this offering were $16.1 million, before deducting underwriting discounts and offering expenses payable by Leap.]]>https://www.globenewswire.com/news-release/2018/03/23/1449432/0/en/Leap-Therapeutics-Announces-Pricing-of-14-Million-Public-Offering-of-Common-Stock.html?f=22&fvtc=4&fvtv=31225Leap Therapeutics Announces Pricing of $14 Million Public Offering of Common Stock2018-03-23T13:00:00Z<![CDATA[CAMBRIDGE, Mass., March 23, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the pricing of an underwritten public offering of 1,866,667 shares of its common stock at a public offering price of $7.50 per share. The gross proceeds to Leap from this offering are expected to be approximately $14.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Leap. All shares of common stock to be sold in the offering are being sold by Leap. In addition, Leap has granted to the underwriters a 30-day option to purchase up to an aggregate of an additional 280,000 shares of its common stock offered in the public offering at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about March 27, 2018, subject to satisfaction of customary closing conditions.]]>https://www.globenewswire.com/news-release/2018/03/22/1444717/0/en/Leap-Therapeutics-Announces-Proposed-Public-Offering-of-Common-Stock.html?f=22&fvtc=4&fvtv=31225Leap Therapeutics Announces Proposed Public Offering of Common Stock2018-03-22T20:05:00Z<![CDATA[CAMBRIDGE, Mass., March 22, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that it has commenced an underwritten public offering of its common stock. All shares of common stock to be sold in the offering will be offered by Leap. Leap intends to grant the underwriters a 30-day option to purchase up to an aggregate of an additional 15% of the shares of its common stock offered in the public offering. The offering is subject to market, regulatory and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.]]>https://www.globenewswire.com/news-release/2018/03/21/1443446/0/en/Leap-Therapeutics-to-Present-at-the-2018-Needham-Company-17th-Annual-Healthcare-Conference.html?f=22&fvtc=4&fvtv=31225Leap Therapeutics to Present at the 2018 Needham & Company 17th Annual Healthcare Conference2018-03-21T11:00:00Z<![CDATA[CAMBRIDGE, Mass., March 21, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced that Christopher K. Mirabelli, Ph.D, Chairman, President, and Chief Executive Officer, will present a corporate overview at the 2018 Needham & Company 17th Annual Healthcare Conference, being held in New York City on March 27-28, 2018.]]>https://www.globenewswire.com/news-release/2018/03/14/1422778/0/en/Leap-Therapeutics-Provides-DKN-01-Program-Update-and-Announces-Scientific-Presentations-at-AACR-Annual-Meeting.html?f=22&fvtc=4&fvtv=31225Leap Therapeutics Provides DKN-01 Program Update and Announces Scientific Presentations at AACR Annual Meeting2018-03-14T21:00:00Z<![CDATA[CAMBRIDGE, Mass., March 14, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today presented promising clinical data from the study evaluating DKN-01, Leap’s anti-DKK1 monoclonal antibody, as a monotherapy in patients with advanced esophagogastric cancer. In addition, Leap announced that the first patient has been enrolled in the study evaluating DKN-01 in patients with gynecological cancers. Leap also announced two upcoming scientific presentations at the American Association for Cancer Research (AACR) 2018 Annual Meeting.]]>